Semaglutide 2 mg Escalation Tied to Lower MACE vs Tirzepatide Switch in T2D
Steady2 outlets reported this in 2 reports over 2 days
After publishing: 1 description edited1 change
- pharmacytimes.comseen 4 Oct, 08:15description edited
what the description said, before and after
A Novo Nordisk-funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, though the findings cannot show causation.A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Thu, 15 October 2026Sat, 17 October 2026
What it is about
Who published it, and when
original reportedited after publishingfirst to report
pharmacytimes.com
hcplive.com
15 Oct, 15:57over 39 hours17 Oct, 06:30
How it spread - 2 original reports
Thu, 15 October 2026
1 report- pharmacytimes.com15:57first to reportedited after publishing
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Sat, 17 October 2026
1 report- hcplive.com06:30
Real-world COMPETE SWITCH CV data at EASD 2026 linked semaglutide 2 mg escalation to 6% lower MACE risk vs switching to tirzepatide in T2D.